| Patient | John Henry Holliday |
|---|---|
| Date of birth | 1851-08-14 |
| Identifiers | MRN HR-NI007-SYN-TD; SSN (made up) 000-07-8153 |
| Document date | 1873-02-24 |
| Author | Martin Beaumont, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week follow-up on tuberculosis treatment, seen the same day by infectious diseases. [S]
Mr. Holliday is a 21-year-old dentist with cavitary pulmonary tuberculosis who returns two weeks after diagnosis and is seen by infectious diseases today. He started isoniazid, rifampin, pyrazinamide, ethambutol, and pyridoxine two days after the first visit, once the nucleic acid amplification test confirmed tuberculosis, and has taken all thirteen doses on daily video calls with the health department nurse. His cough is less frequent, the blood streaks in his sputum have stopped, and the night sweats are lighter. He has mild nausea in the hour after the morning doses, eased by taking them at bedtime with a small snack. His urine and tears are orange, as he was warned. He has no yellowing, dark urine, abdominal pain, rash, numbness, or change in vision or color. He is isolating at home and not working; his roommate is being tested by the health department. He has cut down to a drink or two on three evenings in the two weeks and has not played cards. He feels low about being away from his practice but has no thoughts of suicide. [S]
| Element | Detail |
|---|---|
| Treatment | Thirteen of thirteen doses observed by video |
| Symptoms | Less cough, no further blood in the sputum, lighter night sweats |
| Side effects | Mild nausea after morning doses; orange urine and tears |
| Alcohol | Cut down; AUDIT-C 4 for the past two weeks |
| Isolation | At home; off work |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Cough less frequent; no blood in the sputum for a week; no breathlessness |
| Constitutional | Positive | Lighter night sweats; no fever for five days; appetite returning |
| Gastrointestinal | Positive | Mild nausea after doses; no vomiting, abdominal pain, or jaundice |
| Eyes | Negative | No blurred vision or change in color vision |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Positive | Low about isolation and time off work; no thoughts of suicide or self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for six months | Oral route | 1873-02-12 to 1873-08-13 | completed | S |
| Rifampin 300 mg capsules, two capsules (600 mg) daily | 600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six months | Oral route | 1873-02-12 to 1873-08-13 | completed | S |
| Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily | 1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase | Oral route | 1873-02-12 to 1873-04-08 | completed | S |
| Ethambutol 400 mg tablets, three tablets (1200 mg) daily | 1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results return | Oral route | 1873-02-12 to 1873-03-10 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1873-02-12 to 1873-08-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1873-02-24 | Body height | 178 | cm | S |
| 1873-02-24 | Body weight | 59 | kg | S |
| 1873-02-24 | Body mass index (BMI) [Ratio] | 18.6 | kg/m2 | S |
| 1873-02-24 | Systolic blood pressure | 114 | mm[Hg] | S |
| 1873-02-24 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1873-02-24 | Heart rate | 92 | /min | S |
| 1873-02-24 | Respiratory rate | 18 | /min | S |
| 1873-02-24 | Body temperature | 37.3 | Cel | S |
| 1873-02-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1873-02-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 7-56 U/L | Normal | S |
| 1873-02-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 39 | U/L | 10-40 U/L | Normal | S |
| 1873-02-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1873-02-24 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 1873-02-24 | Visual acuity uncorrected Left eye by ETDRS eye chart | 84 | {letters} | >=80 | Normal | S |
| 1873-02-24 | Total score [AUDIT-C] | 4 | {score} | S |
Vital signs recorded on 1873-02-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, less tired; weight 59.0 kg, up 1.0 kg; temperature 37.3 °C, heart rate 92; seen in a negative-pressure room with a respirator |
| Eyes | No icterus. Visual acuity 85 letters on the right and 84 on the left; Ishihara plates read correctly with each eye |
| Respiratory | Coarse crackles and bronchial breathing over the right upper zone, less than two weeks ago |
| Abdomen | Soft and non-tender; liver not enlarged |
| Neurological | Normal sensation and reflexes in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic. |
| Alcohol use disorder, mild, with binge drinking | active | confirmed | F10.10 | S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | At least monthly during treatment | Completed today | Cough and night sweats improving; no hemoptysis for a week |
| Examination | Weight | At least monthly during treatment | Completed today | 59.0 kg, up 1.0 kg |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | Mild nausea only, eased by bedtime dosing; no jaundice, dark urine, or pain |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, at two weeks, then monthly because of alcohol use | Completed today | ALT 41, AST 39 U/L, bilirubin 0.7 mg/dL, all normal |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Completed today | 85 letters on the right and 84 on the left; color vision normal |
| Laboratory | Nucleic acid amplification test with rifampin resistance | At diagnosis | Up to date | Mycobacterium tuberculosis detected, rifampin resistance not detected, on the first sample |
| Laboratory | Sputum AFB smear and culture | Monthly until two consecutive cultures are negative | Completed today | Baseline smears 2+, 2+, and 3+; cultures growing Mycobacterium tuberculosis complex; release smears ordered for next week |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Ordered | Pending on the baseline isolate |
| Laboratory | HIV test | At diagnosis | Up to date | HIV-1/2 antigen and antibody test negative at diagnosis |
| Laboratory | Hepatitis B and C serology | At diagnosis | Up to date | Hepatitis B surface antigen, surface antibody, and core antibody negative; hepatitis C antibody negative; not immune to hepatitis B |
| Laboratory | Diabetes screen | At diagnosis | Up to date | HbA1c 5.2 percent at diagnosis |
| Imaging | Chest X-ray | At diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baseline | Up to date | Right upper lobe cavity at diagnosis |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | Thirteen of thirteen doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine 50 mg daily |
| Medication safety | Rifampin drug-interaction review | With every new medicine | Completed today | No other medicines; told that rifampin interacts with many drugs and stains contact lenses |
| Self-management | Home isolation and the criteria for release | Until three negative smears, clinical improvement, and two weeks of treatment | Completed today | Isolating at home with no visitors; off work |
| Referral | Contact investigation (household, coworkers, patients) | Led by the health department, from diagnosis | Referred | Health department testing his roommate and assessing coworkers and the patients he treated in the last three months; their results are not part of his record |
| Referral | Report to the local health department | At diagnosis | Up to date | Reported the day of diagnosis |
| Survey | Alcohol use (AUDIT-C for the past month) | Every visit | Completed today | AUDIT-C 4 for the past two weeks, down from 9 |
| Self-management | Brief counseling about alcohol and liver risk | Every visit | Completed today | Agreed goal of no alcohol during treatment |
| Referral | Counseling with a substance-use counselor | Every one to two weeks during treatment | Ordered | First video session next week |
| Medication safety | Medication for alcohol use disorder | Offered for alcohol use disorder | Not indicated | Acamprosate offered; he prefers counseling first for a mild disorder |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide; the 988 Suicide & Crisis Lifeline is in his phone |
| Referral | Infectious diseases consultation | Once at diagnosis, then as advised | Completed today | Seen today |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Release smears next week. Five-week review with susceptibility results. Call the same day for hepatitis symptoms. Next scheduled visit 1873-03-17: five-week review: susceptibility results, release from isolation, and liver monitoring. [S]